(Health-NewsWire.Net, December 24, 2016 ) The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. Report Highlights:
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
For more information about this report at http://www.reportsweb.com/cystic-fibrosis-pipeline-review-h2-2016
Scope:
- The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis - The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects - The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001435870/sample
Reasons to buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Key Companies profiles Actelion Ltd Alaxia SAS AlgiPharma AS AmpliPhi Biosciences Corporation Arch Biopartners, Inc. Arcturus Therapeutics, Inc. Aridis Pharmaceuticals LLC AstraZeneca Plc Bayer AG BioAegis Therapeutics, Inc. Boehringer Ingelheim GmbH Calista Therapeutics, Inc. Catabasis Pharmaceuticals, Inc.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001435870/discount
Few Points from List of Figures:
Number of Products under Development for Cystic Fibrosis, H2 2016 24 Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H2 2016 25 Number of Products under Development by Companies, H2 2016 26 Number of Products under Investigation by Universities/Institutes, H2 2016 32 Comparative Analysis by Late Stage Development, H2 2016 33 Comparative Analysis by Clinical Stage Development, H2 2016 34 Comparative Analysis by Early Stage Products, H2 2016 35 Comparative Analysis by Unknown Stage Development, H2 2016 36 Assessment by Monotherapy Products, H2 2016 120 Assessment by Combination Products, H2 2016 121 Number of Products by Top 10 Targets, H2 2016 122 Number of Products by Stage and Top 10 Targets, H2 2016 122 Number of Products by Top 10 Mechanism of Actions, H2 2016 126 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 126 Number of Products by Routes of Administration, H2 2016 130 Number of Products by Stage and Routes of Administration, H2 2016 130 Number of Products by Top 10 Molecule Types, H2 2016 132 Number of Products by Stage and Top 10 Molecule Types, H2 2016 132 Contact Us: Call: +1-646-491-9876 Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|